Chronic cardiovascular diseases, such as hypertension, arrhythmia and heart failure, are among the leading causes of death worldwide. Our key treatments, such as LOXEN®, acquired in 2018, provide an effective response to these challenges.
Protect the most
precious asset
our health
Since 2015, LXO Group is a leading
integration platform for mature medicines
that are essential for millions of patients
and healthcare professionals.
Our mission
Thanks to our expertise, we are a key European player in Global healthcare.
Cardiovascular system
Central nervous system
Proven treatments for the effective management of neurological disorders, whether chronic (such as MANTADIX®, acquired in 2016) or urgent (such as NIMOTOP®, acquired in 2023), are part of our portfolio of medications recognized by neurology professionals.
Value added medecine
We are committed to protecting family health by offering established medicines with years of proven efficacy and safety.
Our strengths
In less than 10 years, we have turned our mission into a real success story
20
Acquisitions since 2015
Excellence
We are experts in the identification, acquisition and integration of essential drugs and the entire pharmaceutical supply chain.
21
Products in the portfolio
Agility
We aim to be ever more innovative and agile, thanks to the strength of our partners and collaborations.
+80
Countries supplied with our medicines
International
Our teams make our expertise shine, working to ensure access and availability of our medicines worldwide.
+60
Employees in France, Ireland and the United States
Join us
Join a group that recognizes both your skills and your values.
-
Inclusive corporate culture
-
Fast-growing group
-
Supporting professional development
LXO news
